Clinicopathologic and prognostic significance of human epidermal growth factor receptor in patients with gastric cancer: An update meta-analysis.

Clinicopathologic and prognostic significance of human epidermal growth factor receptor in patients with gastric cancer: An update meta-analysis.

Oncotarget. 2017 Feb 09;:

Authors: Zhang Z, Tang H, Lin J, Hu Y, Luo G, Luo Z, Cheng C, Wang P

Abstract
PURPOSE: The aim of this update meta-analysis was to clarify the clinicopathologic and prognostic significance of human epidermal growth factor receptor(EGFR) expression in gastric cancer patients.
EXPERIMENTAL DESIGN: Several electronic databases were searched from January 1970 to May 2016. The odds ratio (OR) was calculated to assess the association between EGFR expression and pathological parameters. The hazard ratio (HR) and 95% CI were calculated to explore the relationship between EGFR expression and overall survival.
RESULTS: Finally 7229 patients with gastric cancer from 25 eligible studies were included in the present meta analysis. High EGFR expression was found to be significantly related with tumor differentiation (OR=1.96, 95%CI: 1.14-3.34, Z=2.43, P=0.015), lymph node metastasis (OR=2.20, 95% CI: 1.63-2.96, Z=5.17, P=0.001), and tumor stage (OR=2.13, 95% CI: 1.35-3.36, Z=3.25, P=0.001). However, high EGFR expression was not significantly associated with invasion depth (OR=2.09, 95% CI: 0.4-11.05, Z=0.87, P=0.385). The pooled HR suggested that high EGFR expression was significantly correlated with overall survival (HR=1.19, 95% CI 1.04-1.37, Z=2.44, P=0.015).
CONCLUSIONS: The present meta-analysis demonstrated that high EGFR expression significantly predicts poor prognosis, suggesting that high EGFR expression may serve as a predictive biomarker for poor prognosis in patients with gastric cancer.

PMID: 28199988 [PubMed - as supplied by publisher]

http://ift.tt/2laJgGz